Chimeric Therapeutics (ASX:CHM) has reported encouraging early results from its CHM CDH17 program, which were presented at the American Society of Clinical Oncology.
In the phase 1 portion of the phase 1/2 study, 9 of 11 evaluable patients achieved stable disease by RECIST criteria, and two patients maintained stability for 12 and more than 15 months, respectively, with three patients still on study at the time of the data snapshot dated May 12 2026.
Sixteen subjects were enrolled, with two screen failures, and 12 were treated after successful manufacturing runs. Treated patients received the product across three dose levels, with enrollment to Dose Level 3 ongoing. Across all dose levels, CHM CDH17 CAR T cells expanded and persisted in peripheral blood for up to 15 months, an observation the company describes as de-risking the asset.
Safety findings were consistent with expectations for cell therapy and for lymphodepleting chemotherapy. All patients experienced treatment-emergent adverse events largely related to lymphodepletion. There was one dose-limiting toxicity, and grade 3 treatment-related events included cytokine release syndrome, enterocolitis, neutropenic fever, and fatigue. There were no grade 4 or 5 treatment-related adverse events.
The study is a two-stage design intended to identify a recommended phase 2 dose and to evaluate safety and objective response in advanced colorectal, gastric, and intestinal neuroendocrine tumours.
Dr Rebecca McQualter, CEO of Chimeric Therapeutics, said, “It’s very pleasing to see these continued positive results and a proud moment for the company to have them presented at ASCO. We look forward to continuing at Dose Level 3 and determining the dose appropriate for Phase 2.”